Timing of changing therapy from gemcitabine and cisplatin chemotherapy based on real-world data of advanced urothelial carcinoma

Cisplatin-based systemic chemotherapy is the gold-standard approach for the first-line treatment of patients with advanced or metastatic urothelial carcinoma (UC). However, the optimal number of cycles is still unclear. The current study retrospectively assessed the clinical outcome in patients who...

Descripción completa

Detalles Bibliográficos
Autores principales: Furubayashi, Nobuki, Negishi, Takahito, Takamatsu, Dai, Ieiri, Kosuke, Inoue, Tomohiro, Tsukino, Keiji, Nakamura, Motonobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074169/
https://www.ncbi.nlm.nih.gov/pubmed/32256805
http://dx.doi.org/10.3892/ol.2020.11368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074169/
https://www.ncbi.nlm.nih.gov/pubmed/32256805
http://dx.doi.org/10.3892/ol.2020.11368

Ejemplares similares